NEW YORK (GenomeWeb News) – Medison will make available CardioDx's Corus CAD diagnostic test for obstructive coronary artery disease in Israel as part of an agreement announced today.

Under the terms of the deal, Medison will market and sell Corus CAD in Israel, where heart disease is the second-leading cause of death and responsible for 16 percent of all deaths annually, the companies said. Blood samples from patients in Israel will be shipped to CardioDx's CLIA-certified laboratory in Palo Alto, Calif., for analysis and test reporting.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Technology Review reports that researchers in the US have used CRISPR to modify a number of human embryos.

By introducing genes from butterfly peas and Canterbury bells, researchers in Japan have developed a blue chrysanthemum, according to NPR.

Plant researchers plan to sequence some 10,000 samples that represent the major plant clades, ScienceInsider reports.

In Nature this week: a Danish reference genome, and more.